5-(Trifluoromethyl)indole | CAS:100846-24-0

We serve 5-(Trifluoromethyl)indole CAS:100846-24-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-(Trifluoromethyl)indole

Chemical Name:5-(Trifluoromethyl)indole
CAS.NO:100846-24-0
Synonyms:5-(Trifluoromethyl)indole
5-(Trifluoromethyl)-1H-indole
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 256.7±35.0 °C at 760 mmHg
Melting Point 67-69°C
Molecular Formula C9H6F3N
Molecular Weight 185.146
Flash Point 109.0±25.9 °C
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.556
 
Specification:
Appearance:Off-white to yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 5-(Trifluoromethyl)indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(Trifluoromethyl)-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(Trifluoromethyl)-1H-indole Use and application,5-(Trifluoromethyl)indole technical grade,usp/ep/jp grade.


Related News: What’s the background?3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine manufacturer The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days.Methyl 4-bromobenzoate supplier The novel coronavirus has resulted in thousands of confirmed human infections in more than 20 countries, with more than 99 percent of cases in China.1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanone vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.